Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Syfovre Vision Side Effects Cases Reported at Ophthalmology Meeting

November 15, 2023 By Law Offices of Thomas J. Lamb, P.A.

A Syfovre vision side effects cases presentation was one of the most important at the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO) in San Francisco in early November. William J. Johnson, M.D., of the Wolfe Clinic in Iowa, reported on Syfovre vision side effects cases ranging from hemorrhagic occlusive vasculitis-type … [Read more...]

Filed Under: Uncategorized, Unsafe Drugs Tagged With: blindness, eye inflammation, occlusive retinal vasculitis, Syfovre, vision loss

Pembrolizumab Plus Lenvatinib as Second- and Third-Line Treatments of Pleural Mesothelioma

October 31, 2023 By Law Offices of Thomas J. Lamb, P.A.

In a Dutch single-institution phase II trial (PEMMELA) reported in The Lancet Oncology, Douma et al found that the combination of pembrolizumab and lenvatinib showed activity as second- and third-line treatments of patients with pleural mesothelioma. Study Details A total of 38 evaluable patients with disease progression after … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, pleural mesothelioma

Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study

October 26, 2023 By Law Offices of Thomas J. Lamb, P.A.

Patients who use drugs containing semaglutide are at an increased risk of gastroparesis, according to an October 2023 medical journal article about patients who used two different types of weight-loss drugs. The Novo Nordisk drugs Wegovy, Rybelsus, and Ozempic each have semaglutide as their active ingredient. Accordingly, Wegovy, Rybelsus, and … [Read more...]

Filed Under: Unsafe Drugs Tagged With: gastrointestinal-related adverse events, gastroparesis, Ozempic, Rybelsus, Wegovy

Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study

October 17, 2023 By Law Offices of Thomas J. Lamb, P.A.

Background:  The combination of pembrolizumab, an anti-PD-1 antibody, and lenvatinib, an antiangiogenic multikinase inhibitor, shows synergistic activity in preclinical and clinical studies in solid tumours. We assessed the clinical activity of this combination therapy in patients with pleural mesothelioma who progressed after platinum-pemetrexed … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma treatments, pleural mesothelioma

Retinal Vasculitis Cases Caused by Syfovre Injection Kits With a 19-gauge Filter Needle?

October 17, 2023 By Law Offices of Thomas J. Lamb, P.A.

In what seems to be the latest Syfovre safety update, in early October 2023 Apellis reported an increase in the number of Syfovre retinal vasculitis cases, but Apellis did not provide any significant new information regarding an “explanation” as to how certain Syfovre injection kits might have caused these adverse reaction events. EndPoints News … [Read more...]

Filed Under: Unsafe Drugs Tagged With: retinal vasculitis, Syfovre

Ozempic Gastrointestinal-related Adverse Events Cases Increasing

October 3, 2023 By Law Offices of Thomas J. Lamb, P.A.

The number of Ozempic gastrointestinal-related adverse events cases, including ileus cases, that have been reported to the FDA during the first 6 months of 2023 was covered in this September 28, 2023 article, “FDA Adds New Warning for Ileus to Semaglutide (Ozempic) Label”, published September 28, 2023, on the HCPLive® website: According to the US … [Read more...]

Filed Under: Unsafe Drugs Tagged With: gastric stasis, gastrointestinal-related adverse events, gastroparesis, ileus, Ozempic, Rybelsus, stomach paralysis, Wegovy

Exhaled Breath May Predict Treatment Outcomes in Patients With Mesothelioma

September 21, 2023 By Law Offices of Thomas J. Lamb, P.A.

The identification of volatile organic compounds (VOCs) in exhaled breath is a promising opportunity for noninvasive detection and prediction of treatment outcomes in patients with mesothelioma, according to data from a pilot study presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, held … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Study Questions Use of Aggressive Surgery in Early Mesothelioma

September 18, 2023 By Law Offices of Thomas J. Lamb, P.A.

Extended pleurectomy decortication combined with platinum and pemetrexed chemotherapy was associated with worse outcomes in patients with resectable mesothelioma compared with chemotherapy alone, according to a randomized trial. “As a surgeon, you have no idea how much it pains me to conclude that extended pleurectomy decortication — an … [Read more...]

Filed Under: Mesothelioma Tagged With: decortication, mesothelioma, mesothelioma treatments, platinum-pemetrexed chemotherapy, pleurectomy

Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis

September 15, 2023 By Law Offices of Thomas J. Lamb, P.A.

In recent years we have seen an increasing number of adverse event reports for three Novo Nordisk semaglutide-containing drugs — Ozempic, Rybelsus, and Wegovy — that involve severe stomach conditions, including: Gastroparesis Gastric Stasis Stomach Paralysis The most common symptoms are nausea and vomiting, which can be severely … [Read more...]

Filed Under: Unsafe Drugs Tagged With: gastric stasis, gastroparesis, Ozempic, Rybelsus, semaglutide-containing drugs, stomach paralysis, Wegovy

Ozempic Gastric Side Effects: Gastroparesis, Stomach Paralysis, Intestinal Blockages

September 6, 2023 By Law Offices of Thomas J. Lamb, P.A.

In the several years since Ozempic was approved by the FDA, there have been adverse event reports of Ozempic gastric side effects such as gastroparesis, stomach paralysis, and intestinal blockage cases in patients using Ozempic. Gastroparesis may also be called delayed gastric emptying. Gastroparesis is a long-term, chronic condition that can be … [Read more...]

Filed Under: Unsafe Drugs Tagged With: gastroparesis, intestinal blockages, Ozempic, stomach paralysis, Wegovy

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 22
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call 910-256-2971 to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

910-256-2971

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.